United States-based Merck has received approval from the US Food and Drug Administration (FDA) for its human papillomavirus 9-valent vaccine, Gardasil 9, to be utilised as treatment for women and men aged from 27 years to 45 years, it was reported yesterday.
The company's supplemental application has been approved to expand the use of Gardasil 9, which helps in preventing certain cancers and diseases caused by the nine HPV types covered by the vaccine.
According to the Center for Disease Control and Prevention (CDC), around 14 million Americans are affected with human papillomavirus each year, and human papillomavirus viruses are associated with several other forms of cancer affecting men and women. Gardasil 9 had already received approval for use in males and females aged between nine years and 26 years.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML